Olaris CEO Joins New AACR Working Group on Cancer Evolution

Why is cancer so hard to treat? How can we overcome resistance? Cancer is an everchanging disease-and many of the greatest treatment challenges are driven by clonal evolution. We must adapt to keep up!

In a great step, the AACR has formed the new Cancer Evolution working group, with Olaris CEO Dr. Liz O'Day on the Steering Committee. Co-chaired by Frank Laukien, CEO of Bruker, and Charles Swanton of the Francis Crick and UCL Cancer Institutes, this group of experts will translate cutting-edge research into new diagnostic, therapeutic, and prevention strategies.

A new way of treating cancer is coming, and biomarkers will be the guide!